作者: Seah Nisam
DOI: 10.1007/978-94-011-5254-9_41
关键词:
摘要: In less than two decades since Michel Mirowski introduced the implantable cardioverter/defibrillator (ICD) into clinical practice, it has been acknowledged as most effective therapy for protecting patients against sudden arrhythmic death, due to ventricular tachycardia or fibrillation (VT/VF)1–3. Many factors have contributed elevating ICD from a treatment “of last resort” primary intervention such patients. Certainly, growing evidence that no antiarrhythmic drugs able improve survival played major role. However, without improvements in technology, resulting implantation procedures similar cardiac pacing, is unlikely would attained current high degree of acceptance — by physicians and The obvious aspects this technological evolution are size. transvenous implantation, device reliability longevity, ease-of-use. At same time, continued pressure on health expenditures brought great focus proving cost-effectiveness, so authorities grant reimbursement sophisticated technology. questions which we will address chapter concern particular balance between cost-effectiveness rapid improvements.